LBB Specialties and Clariant Collaborate for Better Ophthalmic Solutions
In a strategic move poised to reshape the North American pharmaceutical landscape, LBB Specialties (LBBS) has joined forces with Clariant, a prominent global manufacturer of specialty chemicals. This partnership enables LBB Specialties to distribute Clariant's superior pharmaceutical-grade polyethylene glycols (PEGs) and the VitiPure® product line, specifically targeting applications in ophthalmology.
Strengthening Capabilities in Ophthalmic Applications
The collaboration is set to leverage LBB Specialties' established reputation within the ophthalmic sector, merging expertise that spans decades via Clariant's deep-rooted experience in the production of high-quality PEGs. These excipients have proven essential in a myriad of ophthalmic formulations, enhancing product performance and patient outcomes.
Seth Burns, Senior Vice President of Life Sciences at LBB Specialties, highlighted the commitment to delivering top-tier specialty pharmaceutical ingredients. “Our partnership with Clariant enables us to supply industry-leading powders that guarantee consistent performance in ophthalmic applications,” he stated, recognizing the growing demands of the pharmaceutical product lifecycle from research and development through to commercialization.
Benefits to Formulators and Manufacturers
With the addition of Clariant's PEGs into LBB Specialties' innovative Life Sciences portfolio, customers now have enhanced access to high-performance ingredients tailored for various ophthalmic products, such as eye drops and gels. The objective of this partnership is not merely to supply, but to advance the innovation within the field of ophthalmology, ensuring formulators can rely on top-quality components as they develop new solutions.
Vaios Barlas, Head of Health Care at Clariant, also expressed enthusiasm over the partnership. “This collaboration reflects our dedication to serving the pharmaceutical sector via a robust portfolio of top-tier excipients that continuously pushes the boundaries in ophthalmic formulations.” He underscored that through this alliance with LBB Specialties, Clariant aims to make its cutting-edge ingredients more accessible to manufacturers, ultimately contributing to the drive for innovation in ophthalmic applications.
Industry Impact and Future Prospects
The partnership signals a significant advancement for both companies as they aim to shape the future of ophthalmic formulations within North America. By merging LBB Specialties' distribution prowess with Clariant's high-quality production capabilities, the two companies are set to redefine standards in the pharmaceutical ingredients sector. Their collaboration stands as a beacon for other specialty chemical firms, highlighting the potential for strategic alliances that foster product innovation and market expansion.
To dive deeper into how Clariant's PEGs can elevate your ophthalmic products, do not hesitate to reach out to LBB Specialties today. This partnership not only signifies a union of two industry powerhouses but also heralds a new era of excellence within the pharmaceutical landscape.
About LBB Specialties
LBB Specialties is a dominant player in the distribution of specialty chemicals and ingredients across North America, catering to various sectors including care, nutrition, industrial specialties, and life sciences. You can find out more about their offerings at
www.LBBSpecialties.com.
About Clariant
Clariant stands as a leading specialty chemical company, driven by the mission of providing valuable connections between people and the planet. Their commitment to sustainability leads to innovative solutions across numerous industries. In 2023, Clariant reported a workforce of over 10,000 and sales reaching CHF 4.377 billion. With a portfolio specifically designed for the pharmaceutical industry, Clariant Health Care remains a trusted solution provider for excipients and active pharmaceutical ingredients. Learn more about their products at
www.clariant.com/HealthCare.